A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of osteoporosis and bone density in this randomized controlled trial publication.

However, vitamin D insufficiency might have influenced the effect of ED-71 on BMD.

Who Took Part

The abstract describes 219 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

The researchers conducted a randomized, double-blind, placebo-controlled clinical trial of 219 osteoporotic patients (49-87 yr of age).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Biomarkers, Bone Density, Bone Remodeling, Calcitriol, Calcium and Hip Joint.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 219 patients in people with osteoporosis and bone density.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Osteoporosis and bone density research.